Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2024.02.08

A scenic view of Sai Life Sciences' Integrated Discovery & Development Campus in Hyderabad, featuring modern research buildings, a lush green landscape, and a serene water body with floating lily pads, symbolizing the company’s commitment to sustainability and eco-friendly operations.

Sai Life Sciences releases its Sustainability Report 2023

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), released its Sustainability Report 2022-2023. Developed in accordance with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, the fourth edition of the Sustainability report is based on the theme ‘Steadfast on Sustainability,’ and it articulates the company’s commitment to sustainability and the journey so far. Read the full report here.

Making this announcement, Krishna Kanumuri, CEO & Managing Director, stated, “I am delighted to present our fourth successive Sustainability Report, reflecting our commitment to the sustainability journey and to conduct our business responsibly. In 2023, we reset our Sustainable Development Goals to attain specific Environmental, Social, and Governance (ESG) targets by March 31, 2027. The learnings and insights gleaned from our previous experience have shaped our SDGs for this phase, reflecting confidence in our ability to strive for and achieve more ambitious targets.”

The fourth report released by Sai Life Sciences highlights significant progress in various areas:

Environmental:

  • Joined the Science Based Targets initiative (SBTi), a global body enabling businesses to set ambitious emission reduction targets in line with the latest climate science. Accordingly, the company has committed to set near-term company-wide emission reductions in line with climate science with the SBTi.
  • Joined the Sustainable Markets Initiative (SMI) of Manufacture 2030, fostering collaboration with the company’s pharma partners to implement tangible measures for decarbonizing healthcare supply chains.

Social:

  • Strengthened the company’s commitment to social accountability through the implementation of robust policies addressing labor and human rights. Nurtured an agile workforce by embracing diversity across age and gender at all management levels, with dedicated efforts toward empowering women throughout the organization.

Governance:

  • Established the 'Sustainability Governance Council' to seamlessly integrate sustainability matters into the company’s business strategy and oversee the effective enforcement of the sustainability mandate.

This report underscores the company’s dedication to sustainability and exemplifies the progress made, reinforcing Sai Life Sciences' position as a frontrunner in the pursuit of environmentally conscious and socially responsible business practices.

Share article

More News

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more

2025.08.13

Peptide Science & Beyond: Masterclass & Fireside Chat with IISc Professor, Dr. Jayanta Chatterjee

Sai Life Sciences recently hosted Dr. Jayanta Chatterjee, Associate Professor at the Indian Institute of Science (IISc), Bangalore, for two enriching sessions at its campus. The first was the Masterclass Lecture Series, where Dr. Chatterjee addressed a group of scientists at Sai Life Sciences on “Our Adventures in the de novo Design of Helical Macrocyclic […]
Read more

2025.08.13

From vendor to vanguard: Reimagining India’s role in global life sciences

In a recent article published in ET Edge titled, ‘From Vendor to Vanguard: Reimagining India’s Role in Global Life Sciences,’ Krishna Kanumuri, MD & CEO, Sai Life Sciences, highlighted India’s rapidly unfolding transformation from a vendor to an innovation leader in the global life sciences ecosystem.You can read the full article here: From vendor to vanguard: […]
Read more